A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease

Pharmacological Treatment of Neuropsychiatric Symptoms in Huntington's Disease: A Systematic Review

“… 29 One manually retrieved study reporting results on the neuroprotective effect of minocycline that also reported an improvement in NPS 30 was excluded because this study focused on neuroprotective outcomes rather than the treatment of NPS. A total of 15 studies were included in this review, consisting of five RCTs, 31 , 32 , 33 , 34 , 35 five randomized controlled cross‐over trials 36 , 37 , 38 , 39 , 40 and five non‐randomized trials 41 , 42 , 43 , 44 , 45 (for the flow chart: see Fig. 1 ).…”

“…Ten studies used a global or composite instrument to assess overall effects on NPS. 31 , 32 , 33 , 34 , 37 , 38 , 41 , 42 , 43 , 45 Instruments used are the Unified Huntington's Disease Rating Scale (UHDRS) behavioral domain, the Neuropsychiatric Inventory (NPI), PBA‐s and the Symptom Checklist‐90‐Revised (SCL‐R‐90‐R).…”

“… 31 , 34 , 35 , 36 , 39 , 40 , 41 , 44 , 45 Ten studies additionally assessed treatment effect on cognitive functions. 31 , 32 , 33 , 34 , 37 , 38 , 39 , 40 , 43 , 45 Symptom‐specific and cognitive function scales that were used are listed in Table 2 .…”

“…In 10 studies, a neuropsychiatric symptom score was calculated using the results of the UHDRS behavioral domain, the NPI or the SCL‐90‐R to evaluate the overall effect of pharmacological treatment on overall NPS. 31 , 32 , 33 , 34 , 37 , 38 , 41 , 42 , 43 , 45 …”

“…Six randomized controlled (cross‐over) trials evaluated a neuropsychiatric composite score, all as a secondary outcome. 31 , 32 , 33 , 34 , 37 , 38 …”